Anti-HERG activity and the risk of drug-induced arrhythmias and sudden death.

AIMS Drug-induced QTc-prolongation, resulting from inhibition of HERG potassium channels may lead to serious ventricular arrhythmias and sudden death. We studied the quantitative anti-HERG activity of pro-arrhythmic drugs as a risk factor for this outcome in day-to-day practice. METHODS AND RESULTS All 284,426 case reports of suspected adverse drug reactions of drugs with known anti-HERG activity received by the International Drug Monitoring Program of the World Health Organization (WHO-UMC) up to the first quarter of 2003, were used to calculate reporting odds ratios (RORs). Cases were defined as reports of cardiac arrest, sudden death, torsade de pointes, ventricular fibrillation, and ventricular tachycardia (n = 5591), and compared with non-cases regarding the anti-HERG activity, defined as the effective therapeutic plasma concentration (ETCPunbound) divided by the HERG IC50 value, of suspected drugs. We identified a significant association of 1.93 (95% CI: 1.89-1.98) between the anti-HERG activity of drugs, measured as log10 (ETCPunbound/IC50), and reporting of serious ventricular arrhythmias and sudden death to the WHO-UMC database. CONCLUSION Anti-HERG activity is associated with the risk of reports of serious ventricular arrhythmias and sudden death in the WHO-UMC database. These findings are in support of the value of pre-clinical HERG testing to predict pro-arrhythmic effects of medicines.

[1]  L. Wilton,et al.  Underreporting of suspected adverse drug reactions to newly marketed (“black triangle”) drugs in general practice: observational study , 1998, BMJ.

[2]  S. Viskin,et al.  Torsade de Pointes Due to Noncardiac Drugs: Most Patients Have Easily Identifiable Risk Factors , 2003, Medicine.

[3]  R. Shah,et al.  Pharmacogenetic Aspects of Drug-Induced Torsade de Pointes , 2004, Drug safety.

[4]  M. Lindquist,et al.  A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions , 2002, Pharmacoepidemiology and drug safety.

[5]  A. Camm,et al.  Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. , 2003, Cardiovascular research.

[6]  C. E. Lumley,et al.  The under-reporting of adverse drug reactions seen in general practice , 1986 .

[7]  D. Simi57C,et al.  [Monitoring of adverse reactions to drugs]. , 1976, Srpski arhiv za celokupno lekarstvo.

[8]  S. Viskin,et al.  Long QT syndrome caused by noncardiac drugs. , 2003, Progress in cardiovascular diseases.

[9]  S. Olsson,et al.  The WHO international drug monitoring programme , 2000 .

[10]  A. Hoes,et al.  Non-sedating antihistamine drugs and cardiac arrhythmias -- biased risk estimates from spontaneous reporting systems? , 2002, British journal of clinical pharmacology.

[11]  S. Viskin.  Long QT syndromes and torsade de pointes , 1999, The Lancet.

[12]  Gerald A. Faich,et al.  Factors Affecting Physician Reporting of Adverse Drug Reactions , 1986 .